Role of nonalcoholic fatty liver disease in the development of insulin resistance and diabetes

References

• Farrell GC, Larter CZ. Nonalcoholic fatty liver disease: from steatosis to cirrhosis. Hepatology43(2 Suppl. 1), S99–S112 (2006).
   PubMed Web of Science ®Google Scholar
• Ekstedt M, Franzen LE, Mathiesen UL et al. Long-term follow-up of patients with NAFLD and elevated liver enzymes. Hepatology44(4), 865–873 (2006).
   PubMed Web of Science ®Google Scholar
• Kotronen A, Yki-Jarvinen H. Fatty liver: a novel component of the metabolic syndrome. Arterioscler. Thromb. Vasc. Biol.28(1), 27–38 (2008).
   PubMed Web of Science ®Google Scholar
• Brunt EM. Nonalcoholic steatohepatitis: definition and pathology. Semin. Liver Dis.21(1), 3–16 (2001).
   PubMed Web of Science ®Google Scholar
• Brunt EM, Janney CG, Di Bisceglie AM, Neuschwander-Tetri BA, Bacon BR. Nonalcoholic steatohepatitis: a proposal for grading and staging the histological lesions. Am. J. Gastroenterol.94(9), 2467–2474 (1999).
   PubMed Web of Science ®Google Scholar
• Marchesini G, Brizi M, Morselli-Labate AM et al. Association of nonalcoholic fatty liver disease with insulin resistance. Am. J. Med.107(5), 450–455 (1999).
   PubMed Web of Science ®Google Scholar
• Cortez-Pinto H, Chatham J, Chacko VP, Arnold C, Rashid A, Diehl AM. Alterations in liver ATP homeostasis in human nonalcoholic steatohepatitis: a pilot study. JAMA282(17), 1659–1664 (1999).
   PubMed Web of Science ®Google Scholar
• Luyckx FH, Desaive C, Thiry A et al. Liver abnormalities in severely obese subjects: effect of drastic weight loss after gastroplasty. Int. J. Obes. Relat. Metab. Disord.22(3), 222–226 (1998).
   PubMed Web of Science ®Google Scholar
• Marchesini G, Brizi M, Bianchi G et al. Nonalcoholic fatty liver disease: a feature of the metabolic syndrome. Diabetes50(8), 1844–1850 (2001).
   PubMed Web of Science ®Google Scholar
• Bugianesi E, Gastaldelli A, Vanni E et al. Insulin resistance in non-diabetic patients with Nonalcoholic fatty liver disease: sites and mechanisms. Diabetologia48(4), 634–642 (2005).
   PubMed Web of Science ®Google Scholar
• Clark JM, Brancati FL, Diehl AM. The prevalence and etiology of elevated aminotransferase levels in the United States. Am. J. Gastroenterol.98(5), 960–967 (2003).
   PubMed Web of Science ®Google Scholar
• Ruhl CE, Everhart JE. Determinants of the association of overweight with elevated serum alanine aminotransferase activity in the United States. Gastroenterology124(1), 71–79 (2003).
   PubMed Web of Science ®Google Scholar
• Ioannou GN, Weiss NS, Boyko EJ, Kahn SE, Lee SP. Contribution of metabolic factors to alanine aminotransferase activity in persons with other causes of liver disease. Gastroenterology128(3), 627–635 (2005).
   PubMed Web of Science ®Google Scholar
• Friedman LS, Dienstag JL, Watkins E et al. Evaluation of blood donors with elevated serum alanine aminotransferase levels. Ann. Intern. Med.107(2), 137–144 (1987).
   PubMed Web of Science ®Google Scholar
• Wejstal R, Hansson G, Lindholm A, Norkrans G. Persistent alanine aminotransferase elevation in healthy Swedish blood donors-mainly caused by obesity. Vox Sang.55(3), 152–156 (1988).
   PubMed Web of Science ®Google Scholar
• Nakanishi N, Suzuki K, Tatara K. Serum γ-glutamyltransferase and risk of metabolic syndrome and Type 2 diabetes in middle-aged Japanese men. Diabetes Care27(6), 1427–1432 (2004).
   PubMed Web of Science ®Google Scholar
• Hanley AJ, Williams K, Festa A, Wagenknecht LE, D’Agostino RB Jr, Haffner SM. Liver markers and development of the metabolic syndrome: the insulin resistance atherosclerosis study. Diabetes54(11), 3140–3147 (2005).
   PubMed Web of Science ®Google Scholar
• Park HS, Han JH, Choi KM, Kim SM. Relation between elevated serum alanine aminotransferase and metabolic syndrome in Korean adolescents. Am. J. Clin. Nutr.82(5), 1046–1051 (2005).
   PubMed Web of Science ®Google Scholar
• Browning JD, Szczepaniak LS, Dobbins R et al. Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity. Hepatology40(6), 1387–1395 (2004).
   PubMed Web of Science ®Google Scholar
• Ioannou GN, Boyko EJ, Lee SP. The prevalence and predictors of elevated serum aminotransferase activity in the United States in 1999–2002. Am. J. Gastroenterol.101(1), 76–82 (2006).
   PubMed Web of Science ®Google Scholar
• Yoshiike N, Lwin H. Epidemiological aspects of obesity and NASH/NAFLD in Japan. Hepatol. Res.33(2), 77–82 (2005).
   PubMedGoogle Scholar
• Liangpunsakul S, Chalasani N. Unexplained elevations in alanine aminotransferase in individuals with the metabolic syndrome: results from the third National Health and Nutrition Survey (NHANES III). Am. J. Med. Sci.329(3), 111–116 (2005).
   PubMed Web of Science ®Google Scholar
• Nomura H, Kashiwagi S, Hayashi J, Kajiyama W, Tani S, Goto M. Prevalence of fatty liver in a general population of Okinawa, Japan. Jpn. J. Med.27(2), 142–149 (1988).
   PubMedGoogle Scholar
• Franzese A, Vajro P, Argenziano A et al. Liver involvement in obese children. Ultrasonography and liver enzyme levels at diagnosis and during follow-up in an Italian population. Dig. Dis. Sci.42(7), 1428–1432 (1997).
   PubMed Web of Science ®Google Scholar
• Patton HM, Sirlin C, Behling C, Middleton M, Schwimmer JB, Lavine JE. Pediatric nonalcoholic fatty liver disease: a critical appraisal of current data and implications for future research. J. Pediatr. Gastroenterol. Nutr.43(4), 413–427 (2006).
   PubMed Web of Science ®Google Scholar
• Schwimmer JB, Deutsch R, Kahen T, Lavine JE, Stanley C, Behling C. Prevalence of fatty liver in children and adolescents. Pediatrics118(4), 1388–1393 (2006).
   PubMed Web of Science ®Google Scholar
• Fan JG, Li F, Cai XB, Peng YD, Ao QH, Gao Y. Effects of nonalcoholic fatty liver disease on the development of metabolic disorders. J. Gastroenterol. Hepatol.22(7), 1086–1091 (2007).
   PubMedGoogle Scholar
• Suzuki A, Angulo P, Lymp J et al. Chronological development of elevated aminotransferases in a nonalcoholic population. Hepatology41(1), 64–71 (2005).
   PubMed Web of Science ®Google Scholar
• Donnelly KL, Smith CI, Schwarzenberg SJ, Jessurun J, Boldt MD, Parks EJ. Sources of fatty acids stored in liver and secreted via lipoproteins in patients with nonalcoholic fatty liver disease. J. Clin. Invest.115(5), 1343–1351 (2005).
   PubMed Web of Science ®Google Scholar
• Kim SP, Ellmerer M, Van Citters GW, Bergman RN. Primacy of hepatic insulin resistance in the development of the metabolic syndrome induced by an isocaloric moderate-fat diet in the dog. Diabetes52(10), 2453–2460 (2003).
   PubMed Web of Science ®Google Scholar
• Samuel VT, Liu ZX, Qu X et al. Mechanism of hepatic insulin resistance in nonalcoholic fatty liver disease. J. Biol. Chem.279(31), 32345–32353 (2004).
   PubMed Web of Science ®Google Scholar
• Pietilainen KH, Sysi-Aho M, Rissanen A et al. Acquired obesity is associated with changes in the serum lipidomic profile independent of genetic effects – a monozygotic twin study. PLoS ONE2, E218– E218 (2007).
   PubMedGoogle Scholar
• Westerbacka J, Lammi K, Hakkinen AM et al. Dietary fat content modifies liver fat in overweight nondiabetic subjects. J. Clin. Endocrinol. Metab.90(5), 2804–2809 (2005).
   PubMed Web of Science ®Google Scholar
• Pessayre D, Fromenty B. NASH: a mitochondrial disease. J. Hepatol.42(6), 928–940 (2005).
   PubMed Web of Science ®Google Scholar
• Ginsberg HN, Zhang YL, Hernandez-Ono A. Regulation of plasma triglycerides in insulin resistance and diabetes. Arch. Med. Res.36(3), 232–240 (2005).
   PubMed Web of Science ®Google Scholar
• Roden M. Mechanisms of disease: hepatic steatosis in Type 2 diabetes – pathogenesis and clinical relevance. Nat. Clin. Pract. Endocrinol. Metab.2(6), 335–348 (2006).
   PubMedGoogle Scholar
• Utzschneider KM, Kahn SE. Review: the role of insulin resistance in nonalcoholic fatty liver disease. J. Clin. Endocrinol. Metab.91(12), 4753–4761 (2006).
   PubMed Web of Science ®Google Scholar
• Kraegen EW, Clark PW, Jenkins AB, Daley EA, Chisholm DJ, Storlien LH. Development of muscle insulin resistance after liver insulin resistance in high-fat-fed rats. Diabetes40(11), 1397–1403 (1991).
   PubMed Web of Science ®Google Scholar
• Reitman ML. Metabolic lessons from genetically lean mice. Annu .Rev. Nutr.22, 459–482 (2002).
   PubMedGoogle Scholar
• Sanyal AJ, Campbell-Sargent C, Mirshahi F et al. Nonalcoholic steatohepatitis: association of insulin resistance and mitochondrial abnormalities. Gastroenterology120(5), 1183–1192 (2001).
   PubMed Web of Science ®Google Scholar
• Caldwell SH, Swerdlow RH, Khan EM et al. Mitochondrial abnormalities in nonalcoholic steatohepatitis. J. Hepatol.31(3), 430–434 (1999).
   PubMed Web of Science ®Google Scholar
• Lowell BB, Shulman GI. Mitochondrial dysfunction and Type 2 diabetes. Science307(5708), 384–387 (2005).
   PubMed Web of Science ®Google Scholar
• Browning JD, Horton JD. Molecular mediators of hepatic steatosis and liver injury. J. Clin. Invest.114(2), 147–152 (2004).
   PubMed Web of Science ®Google Scholar
• Petersen KF, Befroy D, Dufour S et al. Mitochondrial dysfunction in the elderly: possible role in insulin resistance. Science300(5622), 1140–1142 (2003).
   PubMed Web of Science ®Google Scholar
• Petersen KF, Dufour S, Befroy D, Lehrke M, Hendler RE, Shulman GI. Reversal of nonalcoholic hepatic steatosis, hepatic insulin resistance, and hyperglycemia by moderate weight reduction in patients with Type 2 diabetes. Diabetes54(3), 603–608 (2005).
   PubMed Web of Science ®Google Scholar
• Juurinen L, Tiikkainen M, Hakkinen AM, Hakkarainen A, Yki-Jarvinen H. Effects of insulin therapy on liver fat content and hepatic insulin sensitivity in patients with Type 2 diabetes. Am. J. Physiol. Endocrinol. Metab.292(3), E829–E835 (2007).
   Google Scholar
• Wanless IR, Lentz JS. Fatty liver hepatitis (steatohepatitis) and obesity: an autopsy study with analysis of risk factors. Hepatology12(5), 1106–1110 (1990).
   PubMed Web of Science ®Google Scholar
• Chitturi S, Abeygunasekera S, Farrell GC et al. NASH and insulin resistance: insulin hypersecretion and specific association with the insulin resistance syndrome. Hepatology35(2), 373–39 (2002).
   PubMed Web of Science ®Google Scholar
• Marchesini G, Bugianesi E, Forlani G et al. Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome. Hepatology37(4), 917–923 (2003).
   PubMed Web of Science ®Google Scholar
• Bugianesi E, McCullough AJ, Marchesini G. Insulin resistance: a metabolic pathway to chronic liver disease. Hepatology42(5), 987–1000 (2005).
   PubMed Web of Science ®Google Scholar
• Hui JM, Hodge A, Farrell GC, Kench JG, Kriketos A, George J. Beyond insulin resistance in NASH: TNF-α or adiponectin? Hepatology40(1), 46–54 (2004).
   PubMed Web of Science ®Google Scholar
• Bugianesi E, Pagotto U, Manini R et al. Plasma adiponectin in nonalcoholic fatty liver is related to hepatic insulin resistance and hepatic fat content, not to liver disease severity. J. Clin. Endocrinol. Metab.90(6), 3498–3504 (2005).
   PubMed Web of Science ®Google Scholar
• Cnop M, Havel PJ, Utzschneider KM et al. Relationship of adiponectin to body fat distribution, insulin sensitivity and plasma lipoproteins: evidence for independent roles of age and sex. Diabetologia46(4), 459–469 (2003).
   PubMed Web of Science ®Google Scholar
• Yamauchi T, Kamon J, Minokoshi Y et al. Adiponectin stimulates glucose utilization and fatty-acid oxidation by activating AMP-activated protein kinase. Nat. Med.8(11), 1288–1295 (2002).
   PubMed Web of Science ®Google Scholar
• Kelley DE, McKolanis TM, Hegazi RA, Kuller LH, Kalhan SC. Fatty liver in Type 2 Diabetes mellitus: relation to regional adiposity, fatty acids, and insulin resistance. Am. J. Physiol. Endocrinol. Metab.285(4), E906–E916 (2003).
   PubMed Web of Science ®Google Scholar
• Crespo J, Cayon A, Fernandez-Gil P et al. Gene expression of tumor necrosis factor α and TNF-receptors, p55 and p75, in nonalcoholic steatohepatitis patients. Hepatology34(6), 1158–1163 (2001)
   PubMed Web of Science ®Google Scholar
• Kugelmas M, Hill DB, Vivian B, Marsano L, McClain CJ. Cytokines and NASH: a pilot study of the effects of lifestyle modification and vitamin E. Hepatology38(2), 413–419 (2003).
   PubMed Web of Science ®Google Scholar
• Fernandez-Real JM, Vayreda M, Richart C et al. Circulating interleukin 6 levels, blood pressure, and insulin sensitivity in apparently healthy men and women. J. Clin. Endocrinol. Metab.86(3), 1154–1159 (2001).
   PubMed Web of Science ®Google Scholar
• Senn JJ, Klover PJ, Nowak IA, Mooney RA. Interleukin-6 induces cellular insulin resistance in hepatocytes. Diabetes51(12), 3391–3399 (2002).
   PubMed Web of Science ®Google Scholar
• Yahagi N, Shimano H, Hasty AH et al. Absence of sterol regulatory element-binding protein-1 (SREBP-1) ameliorates fatty livers but not obesity or insulin resistance in Lep(ob)/Lep(ob) mice. J. Biol. Chem.277(22), 19353–19357 (2002).
   PubMed Web of Science ®Google Scholar
• Kim JB, Wright HM, Wright M, Spiegelman BM. ADD1/SREBP1 activates PPARγ through the production of endogenous ligand. Proc. Natl. Acad. Sci. USA95(8), 4333–4337 (1998).
   PubMed Web of Science ®Google Scholar
• Fajas L, Schoonjans K, Gelman L et al. Regulation of peroxisome proliferator-activated receptor γ expression by adipocyte differentiation and determination factor 1/sterol regulatory element binding protein 1: implications for adipocyte differentiation and metabolism. Mol. Cell. Biol.19(8), 5495–5503 (1999).
   PubMed Web of Science ®Google Scholar
• Kolehmainen M, Vidal H, Alhava E, Uusitupa MI. Sterol regulatory element binding protein 1c (SREBP-1c) expression in human obesity. Obes. Res.9(11), 706–712 (2001).
   PubMedGoogle Scholar
• Denechaud PD, Dentin R, Girard J, Postic C. Role of ChREBP in hepatic steatosis and insulin resistance. FEBS Lett.582(1), 68–73 (2008).
   PubMedGoogle Scholar
• Postic C, Dentin R, Denechaud PD, Girard J. ChREBP, a transcriptional regulator of glucose and lipid metabolism. Annu .Rev. Nutr.27, 179–192 (2007).
   PubMedGoogle Scholar
• Petersen KF, Dufour S, Savage DB et al. The role of skeletal muscle insulin resistance in the pathogenesis of the metabolic syndrome. Proc. Natl Acad. Sci. USA104(31), 12587–12594 (2007).
   PubMed Web of Science ®Google Scholar
• Parekh S, Anania FA. Abnormal lipid and glucose metabolism in obesity: implications for nonalcoholic fatty liver disease. Gastroenterology132(6), 2191–2207 (2007).
   PubMed Web of Science ®Google Scholar
• Seppala-Lindroos A, Vehkavaara S, Hakkinen AM et al. Fat accumulation in the liver is associated with defects in insulin suppression of glucose production and serum free fatty acids independent of obesity in normal men. J. Clin. Endocrinol. Metab.87(7), 3023–3028 (2002).
   PubMed Web of Science ®Google Scholar
• Kahn SE, Hull RL, Utzschneider KM. Mechanisms linking obesity to insulin resistance and Type 2 diabetes. Nature444(7121), 840–846 (2006).
   PubMed Web of Science ®Google Scholar
• Adams LA, Angulo P. Treatment of nonalcoholic fatty liver disease. Postgrad. Med. J.82(967), 315–322 (2006).
   PubMed Web of Science ®Google Scholar
• Hickman IJ, Jonsson JR, Prins JB et al. Modest weight loss and physical activity in overweight patients with chronic liver disease results in sustained improvements in alanine aminotransferase, fasting insulin, and quality of life. Gut53(3), 413–419 (2004).
   PubMed Web of Science ®Google Scholar
• Tiikkainen M, Bergholm R, Vehkavaara S et al. Effects of identical weight loss on body composition and features of insulin resistance in obese women with high and low liver fat content. Diabetes52(3), 701–707 (2003).
   PubMedGoogle Scholar
• Belfort R, Harrison SA, Brown K et al. A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis. N. Engl. J. Med.355(22), 2297–2307 (2006).
   PubMed Web of Science ®Google Scholar
• Akyuz F, Demir K, Ozdil S et al. The effects of rosiglitazone, metformin, and diet with exercise in nonalcoholic fatty liver disease. Dig. Dis. Sci.52(9), 2359–2367 (2007).
   PubMed Web of Science ®Google Scholar
• Lutchman G, Promrat K, Kleiner DE et al. Changes in serum adipokine levels during pioglitazone treatment for nonalcoholic steatohepatitis: relationship to histological improvement. Clin. Gastroenterol. Hepatol.4(8), 1048–1052 (2006).
   PubMed Web of Science ®Google Scholar
• Bugianesi E, Gentilcore E, Manini R et al. A randomized controlled trial of metformin versus vitamin E or prescriptive diet in nonalcoholic fatty liver disease. Am. J. Gastroenterol.100(5), 1082–1090 (2005).
   PubMed Web of Science ®Google Scholar
• Angelico F, Burattin M, Alessandri C, Del Ben M, Lirussi F. Drugs improving insulin resistance for nonalcoholic fatty liver disease and/or nonalcoholic steatohepatitis. Cochrane Database Syst. Rev. (1), CD005166 (2007).
   Google Scholar
• Juurinen L, Tiikkainen M, Hakkinen AM, Hakkarainen A, Yki-Jarvinen H. Effects of insulin therapy on liver fat content and hepatic insulin sensitivity in patients with Type 2 diabetes. Am. J. Physiol. Endocrinol. Metab.292(3), E829–E835 (2007).
   Google Scholar
• Katoh S, Hata S, Matsushima M et al. Troglitazone prevents the rise in visceral adiposity and improves fatty liver associated with sulfonylurea therapy – a randomized controlled trial. Metabolism50(4), 414–417 (2001).
   PubMed Web of Science ®Google Scholar
• Orlando R, Azzalini L, Orando S, Lirussi F. Bile acids for nonalcoholic fatty liver disease and/or steatohepatitis. Cochrane Database Syst. Rev. (1), CD005160 (2007).
   Google Scholar
• Lirussi F, Azzalini L, Orando S, Orlando R, Angelico F. Antioxidant supplements for nonalcoholic fatty liver disease and/or steatohepatitis. Cochrane Database Syst. Rev. (1), CD004996 (2007).
   Google Scholar
• Satapathy SK, Sakhuja P, Malhotra V, Sharma BC, Sarin SK. Beneficial effects of pentoxifylline on hepatic steatosis, fibrosis and necroinflammation in patients with nonalcoholic steatohepatitis. J. Gastroenterol. Hepatol.22(5), 634–638 (2007).
   PubMed Web of Science ®Google Scholar
• Guallar E, Hanley DF, Miller ER 3rd. An editorial update: Annus horribilis for vitamin E. Ann. Intern. Med143(2), 143–145 (2005).
   PubMed Web of Science ®Google Scholar
• Ekstedt M, Franzen LE, Mathiesen UL, Holmqvist M, Bodemar G, Kechagias S. Statins in nonalcoholic fatty liver disease and chronically elevated liver enzymes: a histopathological follow-up study. J. Hepatol.47(1), 135–141 (2007).
   PubMed Web of Science ®Google Scholar
• Teixeira-Clerc F, Julien B, Grenard P et al. CB1 cannabinoid receptor antagonism: a new strategy for the treatment of liver fibrosis. Nat. Med.12(6), 671–676 (2006).
   PubMed Web of Science ®Google Scholar
• Tushuizen ME, Bunck MC, Pouwels PJ, van Waesberghe JH, Diamant M, Heine RJ. Incretin mimetics as a novel therapeutic option for hepatic steatosis. Liver Int.26(8), 1015–1017 (2006).
   PubMed Web of Science ®Google Scholar